



We want to save patients with severe cancer and autoimmune diseases
Clinical investigations with our lead antibody CAN04 to our proprietary target

Göran Forsberg, CEO

Safe Harbour Statement


The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are well-considered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.

IL-1 blockade in cancer- Recent supportive clinical data

CANTOS trial

- Canakinumab (Novartis)
- Reduced lung cancer incidence by 67 % and death by 77 %.

CANTOS: Additional Non-Cardiovascular Clinical Benefits Incident Lung Cancer



- Clinical validation of IL-1 pathway
- Cantargia's CAN04 has broader MOA

Canakinumab phase 3 trials

Adjuvant NSCLC

After surgery, no mets, placebo control
1500 patients, recruitment ongoing
Completion 2021/22

First line (CANOPY-1)



Untreated locally advanced/metastatic
Combination Pembro/Platinum doublet
627 patients, start Dec 2018
Completion 2021/22

Second line metastatic (CANOPY-2)

Previously treated loc adv/metastatic
Combination Docetaxel
240 patients, start Dec 2018
Completion 2021

Source clinicaltrials.gov

CAN04 (nidanilimab) vs Canakinumab




Canakinumab


- Antibody directed against one of the two IL-1 ligands, IL-1 β

CAN04:

- Binds the common signaling receptor and counteracts both ligands
- Induce killing via the immune system (ADCC)



Medical need and IL1RAP




Size of each indication corresponds to annual deaths in USA

- Cantargia founded based on:
 - Discovery of IL1RAP on cancer cells
 - Antibodies against IL1RAP - antitumor effects
 - Patents on antibody therapy against IL1RAP
- Primary indications. NSCLC and pancreatic cancer
- Biomarker studies ongoing, identify patients most likely to respond
- Opportunity to expand development in additional cancer forms

CAN04 – CANFOUR clinical trial

Phase I/IIa trial - NSCLC and pancreatic cancer

- Norway, Denmark, Netherlands and Belgium
- Well renowned centres (Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo)
- 15 patients treated, good safety
 - NSCLC, pancreatic cancer, colon cancer, triple negative breast cancer
- Phase IIa: focused on NSCLC and pancreatic cancer (appr 20 centres)
 - Monotherapy
 - Combination with standard therapy
 - NSCLC Cisplatin/Gemcitabine
 - Pancreatic cancer Gemcitabine/nab-paclitaxel



Details on www.clinicaltrials.gov

Cantargia at a glance

- Specialized in antibody therapy/immunology, with initial focus on oncology
- Granted IP - therapeutic target IL1RAP and drug candidate
- Lead antibody CAN04 (nidanilimab) in clinical development
- Strong management team with proven track record in clinical development and business development
- Listed on Nasdaq Stockholm
- More than 4000 shareholders
- Based in Lund, Sweden


Financial highlights

- Share price: 23.10 SEK (2.58 USD), Oct 1, 2018
- Market cap: 1529 MSEK (171 MUSD), Oct 1, 2018
- Cash: 213 MSEK (23.3 MUSD), Jun 30 2018


Current owners (Jun 30, 2018)

Sunstone	9.0%
1st AP fund	6.9%
Avanza Pension	6.0%
4th AP fund	4.6%
SEB S.A. clients	3.5%
2nd AP fund	3.3%
Mats Invest AB	2.0%
Tibia konsult	2.0%
Kudu AB	1.9 %
Brushamn Invest	1.9%
Nordnet Pension	1.9%
SHB Pharm Fund	1.5%
Others	55.5%

Cantargia pipeline





CAN04 attacks several cell types in the tumor




Inflammation and metastasis

- Cancer cells (seeds) need a good soil to form a metastasis
- The IL-1 system (inflammation) can provide such environment (soil)



A tumor can create its own "seed and soil"

NSCLC CAN04/Cisplatin combination




	Control	CAN04	Cisplatin	Combination
Animals withdrawn	20 % (Tumor)	0 %	50 % (Toxicity)	20 % (Toxicity)
Tumor reduction	N/A	14%	18%	52 %
Comment	Highest tumor burden	Best safety	Highest toxicity	Superior efficacy and reduced toxicity

Combination CAN04/Cisplatin superior to individual agents

- Reduction in severe toxicity
- Increased efficacy

IL1RAP - additional potential indications to leverage the value of our asset

- Three different systems signal through IL1RAP
- These systems contribute to various inflammatory diseases
- Can be blocked by Cantargia's antibodies against IL1RAP



Cantargia partnership with Panorama Res Inc (Sunnyvale, CA)
Selection of clinical candidate 2019

Significant value inflection points ahead

2018

- Preclinical data (immuno-oncology effects, combinations etc)
- Phase I clinical data (Q4 2018)
- Initiation of Phase IIa portion of the clinical trial (Q4 2018)
- US regulatory and clinical strategy

2019/2020

- Clinical progress and Phase IIa results
- Preclinical progress
- CANxx progress

Cantargia summary

- Lead candidate antibody CAN04 in clinical trials against cancer
 - Double mechanism of action
 - Initial development in NSCLC and pancreatic cancer (cancer forms with poor prognosis)
 - Direct effects on tumor cells and tumor microenvironment
 - Recent external validation of pathway
- Second generation antibodies for autoimmune disease
- Unique and strong IP
- Strong lead investors with high competence and well known track record
 - Funding through phase IIa - until mid 2020.